Flight Centre Travel Group Limited (ASX:FLT) Shares Could Be 35% Below Their Intrinsic Value Estimate
The projected fair value for Flight Centre Travel Group is AU$21.64 based on 2 Stage Free Cash Flow to Equity
Current share price of AU$14.09 suggests Flight Centre Travel Group is potentially 35% undervalued
The AU$19.81 analyst price target for FLT is 8.5% less than our estimate of fair value
How far off is Flight Centre Travel Group Limited (ASX:FLT) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Don't get put off by the jargon, the math behind it is actually quite straightforward.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
Check out our latest analysis for Flight Centre Travel Group
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Levered FCF (A$, Millions)
AU$286.8m
AU$390.2m
AU$462.2m
AU$342.3m
AU$319.8m
AU$308.4m
AU$303.3m
AU$302.2m
AU$303.9m
AU$307.7m
Growth Rate Estimate Source
Analyst x6
Analyst x6
Analyst x5
Analyst x2
Analyst x1
Est @ -3.56%
Est @ -1.67%
Est @ -0.35%
Est @ 0.58%
Est @ 1.23%
Present Value (A$, Millions) Discounted @ 8.3%
AU$265
AU$333
AU$364
AU$249
AU$214
AU$191
AU$173
AU$159
AU$148
AU$138
("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = AU$2.2b
After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.7%. We discount the terminal cash flows to today's value at a cost of equity of 8.3%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = AU$308m× (1 + 2.7%) ÷ (8.3%– 2.7%) = AU$5.7b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= AU$5.7b÷ ( 1 + 8.3%)10= AU$2.5b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is AU$4.8b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of AU$14.1, the company appears quite undervalued at a 35% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Flight Centre Travel Group as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.3%, which is based on a levered beta of 1.289. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
Strength
Debt is not viewed as a risk.
Weakness
Earnings declined over the past year.
Dividend is low compared to the top 25% of dividend payers in the Hospitality market.
Opportunity
Annual earnings are forecast to grow faster than the Australian market.
Good value based on P/E ratio and estimated fair value.
Threat
Dividends are not covered by cash flow.
Revenue is forecast to grow slower than 20% per year.
Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Why is the intrinsic value higher than the current share price? For Flight Centre Travel Group, there are three essential elements you should look at:
Risks: For instance, we've identified 2 warning signs for Flight Centre Travel Group that you should be aware of.
Future Earnings: How does FLT's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the ASX every day. If you want to find the calculation for other stocks just search here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
KULR Technology Group (NYSEAM:KULR) Announces US$300 Million Follow-on Equity Offering
KULR Technology Group recently announced a follow-on equity offering seeking to raise $300 million, which may support its future growth plans. However, this announcement coincides with a stable upward trend in the broader market, with the S&P 500 closing above 6,000 for the first time since February. KULR Technology's share price increased by 4% over the last week, aligning closely with the overall market's positive trajectory of 1.6%. While the equity offering presents potential value to investors, its influence on the stock's performance should be considered in the context of a generally bullish market environment. We've identified 2 warning signs for KULR Technology Group (1 doesn't sit too well with us) that you should be aware of. Rare earth metals are the new gold rush. Find out which 24 stocks are leading the charge. The recent announcement of KULR Technology Group's US$300 million follow-on equity offering may bolster its growth potential, aligning with its expansion plans in Texas and entry into AI and robotics. Over the past year, KULR's total shareholder return was very large at 277%, highlighting a period of substantial growth for the company. This impressive growth could be linked to its strategic ventures and the broader market's upward movement. Compared to the last year, KULR outperformed the US Electrical industry, which returned 24.1%, and the US market, which returned 12.4%. The broader market context suggests a favorable investor sentiment that could be reinforced by this new equity raise. The company's shares have increased by 4% in the past week, although they remain US$2.53 below the consensus price target of US$4.17, indicating potential upside according to analyst projections. This fundraising initiative might positively influence KULR's revenue and earnings forecasts, as it supports capital and operational expansions that aim to tap into growing markets like AI and robotics. KULR is projected to experience significant annual revenue growth of 64.7%, well above the market average, and aims for earnings improvement from its current losses. The equity offering may enhance its financial flexibility, possibly realizing these future growth expectations. Review our historical performance report to gain insights into KULR Technology Group's track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSEAM:KULR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Discovering Undiscovered Gems in Asia June 2025
As global markets navigate a complex landscape of cooling labor markets and geopolitical tensions, the Asian market presents intriguing opportunities for investors seeking growth potential. In particular, small-cap stocks in Asia are capturing attention due to their resilience and adaptability amid fluctuating economic indicators, making them appealing candidates for those looking to uncover hidden gems in an evolving market environment. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Wuxi Xinan Technology NA 11.99% 4.45% ★★★★★★ Hangzhou Xili Intelligent TechnologyLtd NA 11.73% 9.57% ★★★★★★ Hubei Three Gorges Tourism Group 11.24% -15.32% 17.90% ★★★★★★ Shangri-La Hotel NA 23.33% 39.56% ★★★★★★ Hongmian Zhihui Science and Technology 15.92% -28.99% 46.16% ★★★★★★ Tohoku Steel NA 5.34% -2.26% ★★★★★★ Lee's Pharmaceutical Holdings 13.81% -0.34% -27.47% ★★★★★☆ KC 2.19% 8.76% -0.47% ★★★★★☆ ASRock Rack Incorporation 26.93% 225.32% 6287.64% ★★★★☆☆ Tibet TourismLtd 27.63% 9.10% 17.00% ★★★★☆☆ Click here to see the full list of 2608 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. Let's explore several standout options from the results in the screener. Simply Wall St Value Rating: ★★★★★☆ Overview: ChengDu ShengNuo Biotec Co., Ltd. focuses on the research, development, production, sale, and export of peptide drugs and has a market capitalization of CN¥5.46 billion. Operations: ShengNuo Biotec generates revenue primarily through the sale and export of peptide drugs. The company's financial performance is highlighted by its net profit margin, which has shown significant variation over recent periods. ChengDu ShengNuo Biotec Ltd, a small player in the biotech sector, has shown impressive financial growth recently. Its Q1 2025 earnings reported sales of CNY 184.34 million, a significant jump from CNY 104.06 million the previous year. Net income also rose to CNY 47.12 million from CNY 16.47 million, showcasing strong profitability with basic earnings per share increasing to CNY 0.42 from CNY 0.15 last year. Despite its volatile share price over the past three months, the company's debt is well managed with an EBIT interest coverage of 14 times and a satisfactory net debt to equity ratio of approximately 28%. Click here to discover the nuances of ChengDu ShengNuo BiotecLtd with our detailed analytical health report. Assess ChengDu ShengNuo BiotecLtd's past performance with our detailed historical performance reports. Simply Wall St Value Rating: ★★★★★★ Overview: Innuovo Technology Co., Ltd. operates in the research, development, production, and sale of rare earth permanent magnet materials both in China and internationally, with a market capitalization of CN¥12.20 billion. Operations: The company's revenue primarily stems from the sale of rare earth permanent magnet materials. The net profit margin has shown variability, reflecting changes in cost structures and market conditions. Innuovo Technology, a smaller player in Asia's tech scene, has been making waves with its impressive financial performance. Over the past year, earnings surged by 114%, outpacing the industry average of -4.4%. The company trades at 49% below its estimated fair value, indicating potential undervaluation. Despite a slight dip in sales to CNY 839 million from CNY 895 million last year, net income rose to CNY 69 million from CNY 66 million. Innuovo also announced a final cash dividend of CNY 1.24 per share for A shares in 2024 and completed a significant buyback of nearly 19 million shares worth over CNY106 million. Click to explore a detailed breakdown of our findings in Innuovo Technology's health report. Understand Innuovo Technology's track record by examining our Past report. Simply Wall St Value Rating: ★★★★★★ Overview: Guomai Technologies, Inc. operates in China offering internet of things technology services, consulting and design, science park operation and development, as well as education services with a market cap of CN¥11.88 billion. Operations: Guomai Technologies generates revenue primarily through its internet of things technology services, consulting and design, science park operation and development, and education services. The company focuses on providing comprehensive solutions in these areas to drive its financial performance. Net profit margin trends provide insight into the company's profitability dynamics over time. Guomai Technologies, a debt-free player in the IT sector, stands out with a Price-To-Earnings ratio of 59x, notably lower than the industry average of 85.4x. The company recently reported impressive earnings growth of 67.4% over the past year, significantly outperforming the IT industry's -13.7%. Despite some volatility in its share price recently, Guomai's financial health remains robust with a notable one-off gain of CN¥81.8M impacting its latest results as of March 2025. Additionally, their dividend strategy includes a cash distribution plan offering CN¥0.80 per 10 shares for 2024 profits, indicating solid shareholder returns. Delve into the full analysis health report here for a deeper understanding of Guomai Technologies. Examine Guomai Technologies' past performance report to understand how it has performed in the past. Investigate our full lineup of 2608 Asian Undiscovered Gems With Strong Fundamentals right here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688117 SZSE:000795 and SZSE:002093. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 hours ago
- Yahoo
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
BOSTON & SYDNEY, June 09, 2025--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. "The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey," said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. "Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry". BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich. View source version on Contacts MEDIA CONTACTJoAnn Lee / +1 617.936.2937